Becton, Dickinson and Company (BDX) Stock Competitors & Peer Comparison
See (BDX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDX | $144.43 | -0.62% | 52.3B | 25.25 | $5.72 | +2.44% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.44% |
| ALC | $64.28 | -2.16% | 31.3B | 38.49 | $1.67 | +0.56% |
| MDLN | $33.19 | -7.16% | 28.1B | 29.11 | $1.14 | N/A |
| WST | $312.17 | -1.31% | 22.1B | 41.69 | $7.49 | +0.28% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.44% |
| COO | $59.49 | -1.16% | 11.6B | 29.60 | $2.01 | N/A |
| BAX | $18.68 | +1.52% | 9.6B | -9.78 | -$1.91 | +1.07% |
| ATR | $112.18 | -0.18% | 7.2B | 19.22 | $5.84 | +1.68% |
Stock Comparison
BDX vs BDXA Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BDX is priced at $144.43, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas BDXA's P/E ratio is 21.44. In terms of profitability, BDX's ROE is +0.05%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check BDXA's competition here
BDX vs ALC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ALC has a market cap of 31.3B. Regarding current trading prices, BDX is priced at $144.43, while ALC trades at $64.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ALC's P/E ratio is 38.49. In terms of profitability, BDX's ROE is +0.05%, compared to ALC's ROE of +0.04%. Regarding short-term risk, BDX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ALC's competition here
BDX vs MDLN Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, MDLN has a market cap of 28.1B. Regarding current trading prices, BDX is priced at $144.43, while MDLN trades at $33.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas MDLN's P/E ratio is 29.11. In terms of profitability, BDX's ROE is +0.05%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BDX is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check MDLN's competition here
BDX vs WST Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, WST has a market cap of 22.1B. Regarding current trading prices, BDX is priced at $144.43, while WST trades at $312.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas WST's P/E ratio is 41.69. In terms of profitability, BDX's ROE is +0.05%, compared to WST's ROE of +0.18%. Regarding short-term risk, BDX is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check WST's competition here
BDX vs HOLX Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDX is priced at $144.43, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDX's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check HOLX's competition here
BDX vs BDXB Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDX is priced at $144.43, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDX's ROE is +0.05%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check BDXB's competition here
BDX vs COO Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, COO has a market cap of 11.6B. Regarding current trading prices, BDX is priced at $144.43, while COO trades at $59.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas COO's P/E ratio is 29.60. In terms of profitability, BDX's ROE is +0.05%, compared to COO's ROE of +0.05%. Regarding short-term risk, BDX is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check COO's competition here
BDX vs BAX Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, BAX has a market cap of 9.6B. Regarding current trading prices, BDX is priced at $144.43, while BAX trades at $18.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas BAX's P/E ratio is -9.78. In terms of profitability, BDX's ROE is +0.05%, compared to BAX's ROE of -0.16%. Regarding short-term risk, BDX is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check BAX's competition here
BDX vs ATR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ATR has a market cap of 7.2B. Regarding current trading prices, BDX is priced at $144.43, while ATR trades at $112.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ATR's P/E ratio is 19.22. In terms of profitability, BDX's ROE is +0.05%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDX is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ATR's competition here
BDX vs RGEN Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, RGEN has a market cap of 6.8B. Regarding current trading prices, BDX is priced at $144.43, while RGEN trades at $121.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas RGEN's P/E ratio is 134.59. In terms of profitability, BDX's ROE is +0.05%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check RGEN's competition here
BDX vs AVTR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, AVTR has a market cap of 6.1B. Regarding current trading prices, BDX is priced at $144.43, while AVTR trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas AVTR's P/E ratio is -11.10. In terms of profitability, BDX's ROE is +0.05%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDX is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check AVTR's competition here
BDX vs TFX Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, BDX is priced at $144.43, while TFX trades at $125.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas TFX's P/E ratio is 2088.60. In terms of profitability, BDX's ROE is +0.05%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BDX is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check TFX's competition here
BDX vs BLCO Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, BLCO has a market cap of 5.3B. Regarding current trading prices, BDX is priced at $144.43, while BLCO trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas BLCO's P/E ratio is -24.16. In terms of profitability, BDX's ROE is +0.05%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDX is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check BLCO's competition here
BDX vs STVN Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, STVN has a market cap of 5.1B. Regarding current trading prices, BDX is priced at $144.43, while STVN trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas STVN's P/E ratio is 31.92. In terms of profitability, BDX's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BDX is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check STVN's competition here
BDX vs MMSI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, MMSI has a market cap of 3.6B. Regarding current trading prices, BDX is priced at $144.43, while MMSI trades at $60.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas MMSI's P/E ratio is 26.25. In terms of profitability, BDX's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check MMSI's competition here
BDX vs ICUI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ICUI has a market cap of 3.3B. Regarding current trading prices, BDX is priced at $144.43, while ICUI trades at $130.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ICUI's P/E ratio is 70.53. In terms of profitability, BDX's ROE is +0.05%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check ICUI's competition here
BDX vs WRBY Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, WRBY has a market cap of 3.1B. Regarding current trading prices, BDX is priced at $144.43, while WRBY trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas WRBY's P/E ratio is 2508.50. In terms of profitability, BDX's ROE is +0.05%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, BDX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check WRBY's competition here
BDX vs HAE Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, HAE has a market cap of 3B. Regarding current trading prices, BDX is priced at $144.43, while HAE trades at $66.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas HAE's P/E ratio is 32.37. In terms of profitability, BDX's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BDX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check HAE's competition here
BDX vs LMAT Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, BDX is priced at $144.43, while LMAT trades at $91.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas LMAT's P/E ratio is 33.68. In terms of profitability, BDX's ROE is +0.05%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDX is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check LMAT's competition here
BDX vs XRAY Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, BDX is priced at $144.43, while XRAY trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas XRAY's P/E ratio is -3.12. In terms of profitability, BDX's ROE is +0.05%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BDX is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check XRAY's competition here
BDX vs NVCR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, BDX is priced at $144.43, while NVCR trades at $15.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NVCR's P/E ratio is -10.33. In terms of profitability, BDX's ROE is +0.05%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, BDX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NVCR's competition here
BDX vs PLSE Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, PLSE has a market cap of 1.7B. Regarding current trading prices, BDX is priced at $144.43, while PLSE trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas PLSE's P/E ratio is -22.07. In terms of profitability, BDX's ROE is +0.05%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BDX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check PLSE's competition here
BDX vs NNNN Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NNNN has a market cap of 1.4B. Regarding current trading prices, BDX is priced at $144.43, while NNNN trades at $32.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NNNN's P/E ratio is 218.07. In terms of profitability, BDX's ROE is +0.05%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, BDX is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NNNN's competition here
BDX vs STAA Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, BDX is priced at $144.43, while STAA trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas STAA's P/E ratio is -67.83. In terms of profitability, BDX's ROE is +0.05%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BDX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check STAA's competition here
BDX vs BLFS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, BDX is priced at $144.43, while BLFS trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas BLFS's P/E ratio is -114.54. In terms of profitability, BDX's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check BLFS's competition here
BDX vs ATRC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ATRC has a market cap of 1.3B. Regarding current trading prices, BDX is priced at $144.43, while ATRC trades at $25.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ATRC's P/E ratio is -258.60. In terms of profitability, BDX's ROE is +0.05%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, BDX is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check ATRC's competition here
BDX vs KMTS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, BDX is priced at $144.43, while KMTS trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas KMTS's P/E ratio is -3.45. In terms of profitability, BDX's ROE is +0.05%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, BDX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check KMTS's competition here
BDX vs AZTA Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, AZTA has a market cap of 1.1B. Regarding current trading prices, BDX is priced at $144.43, while AZTA trades at $23.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas AZTA's P/E ratio is -9.72. In terms of profitability, BDX's ROE is +0.05%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BDX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check AZTA's competition here
BDX vs QDEL Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, QDEL has a market cap of 906.3M. Regarding current trading prices, BDX is priced at $144.43, while QDEL trades at $13.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas QDEL's P/E ratio is -0.74. In terms of profitability, BDX's ROE is +0.05%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BDX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check QDEL's competition here
BDX vs ATRI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDX is priced at $144.43, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDX's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ATRI's competition here
BDX vs ANGO Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ANGO has a market cap of 453.7M. Regarding current trading prices, BDX is priced at $144.43, while ANGO trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ANGO's P/E ratio is -14.45. In terms of profitability, BDX's ROE is +0.05%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, BDX is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ANGO's competition here
BDX vs OSUR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, OSUR has a market cap of 275.4M. Regarding current trading prices, BDX is priced at $144.43, while OSUR trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas OSUR's P/E ratio is -3.81. In terms of profitability, BDX's ROE is +0.05%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BDX is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check OSUR's competition here
BDX vs PDEX Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, PDEX has a market cap of 213.1M. Regarding current trading prices, BDX is priced at $144.43, while PDEX trades at $66.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas PDEX's P/E ratio is 18.39. In terms of profitability, BDX's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDX is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check PDEX's competition here
BDX vs UTMD Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, UTMD has a market cap of 212.8M. Regarding current trading prices, BDX is priced at $144.43, while UTMD trades at $66.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas UTMD's P/E ratio is 19.77. In terms of profitability, BDX's ROE is +0.05%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check UTMD's competition here
BDX vs SMTI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, SMTI has a market cap of 195.7M. Regarding current trading prices, BDX is priced at $144.43, while SMTI trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas SMTI's P/E ratio is 356.00. In terms of profitability, BDX's ROE is +0.05%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BDX is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check SMTI's competition here
BDX vs STXS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, STXS has a market cap of 193M. Regarding current trading prices, BDX is priced at $144.43, while STXS trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas STXS's P/E ratio is -8.23. In terms of profitability, BDX's ROE is +0.05%, compared to STXS's ROE of -1.53%. Regarding short-term risk, BDX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check STXS's competition here
BDX vs KRMD Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, KRMD has a market cap of 186M. Regarding current trading prices, BDX is priced at $144.43, while KRMD trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas KRMD's P/E ratio is -81.00. In terms of profitability, BDX's ROE is +0.05%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BDX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check KRMD's competition here
BDX vs INFU Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, INFU has a market cap of 180M. Regarding current trading prices, BDX is priced at $144.43, while INFU trades at $8.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas INFU's P/E ratio is 24.11. In terms of profitability, BDX's ROE is +0.05%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BDX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check INFU's competition here
BDX vs NYXH Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NYXH has a market cap of 110.9M. Regarding current trading prices, BDX is priced at $144.43, while NYXH trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NYXH's P/E ratio is -1.20. In terms of profitability, BDX's ROE is +0.05%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, BDX is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NYXH's competition here
BDX vs MBOT Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, MBOT has a market cap of 91.6M. Regarding current trading prices, BDX is priced at $144.43, while MBOT trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas MBOT's P/E ratio is -7.73. In terms of profitability, BDX's ROE is +0.05%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check MBOT's competition here
BDX vs STSS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, STSS has a market cap of 77.4M. Regarding current trading prices, BDX is priced at $144.43, while STSS trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas STSS's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BDX is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check STSS's competition here
BDX vs AKYA Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDX is priced at $144.43, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDX's ROE is +0.05%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, BDX is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check AKYA's competition here
BDX vs ZTEK Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ZTEK has a market cap of 59.1M. Regarding current trading prices, BDX is priced at $144.43, while ZTEK trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ZTEK's P/E ratio is -9.17. In terms of profitability, BDX's ROE is +0.05%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, BDX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check ZTEK's competition here
BDX vs DXR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, DXR has a market cap of 52.2M. Regarding current trading prices, BDX is priced at $144.43, while DXR trades at $10.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas DXR's P/E ratio is 6.31. In terms of profitability, BDX's ROE is +0.05%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check DXR's competition here
BDX vs OMIC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDX is priced at $144.43, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDX's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check OMIC's competition here
BDX vs IGAP Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDX is priced at $144.43, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDX's ROE is +0.05%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BDX is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check IGAP's competition here
BDX vs POCI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, POCI has a market cap of 43.7M. Regarding current trading prices, BDX is priced at $144.43, while POCI trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas POCI's P/E ratio is -8.84. In terms of profitability, BDX's ROE is +0.05%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check POCI's competition here
BDX vs NEPH Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NEPH has a market cap of 41.3M. Regarding current trading prices, BDX is priced at $144.43, while NEPH trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NEPH's P/E ratio is 54.29. In terms of profitability, BDX's ROE is +0.05%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BDX is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NEPH's competition here
BDX vs MLSS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, MLSS has a market cap of 34.6M. Regarding current trading prices, BDX is priced at $144.43, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas MLSS's P/E ratio is -6.55. In terms of profitability, BDX's ROE is +0.05%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BDX is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check MLSS's competition here
BDX vs HBIO Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, HBIO has a market cap of 29.1M. Regarding current trading prices, BDX is priced at $144.43, while HBIO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas HBIO's P/E ratio is -3.00. In terms of profitability, BDX's ROE is +0.05%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BDX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check HBIO's competition here
BDX vs SDC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDX is priced at $144.43, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check SDC's competition here
BDX vs EKSO Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, BDX is priced at $144.43, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas EKSO's P/E ratio is -2.31. In terms of profitability, BDX's ROE is +0.05%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, BDX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check EKSO's competition here
BDX vs ZJYL Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ZJYL has a market cap of 25.4M. Regarding current trading prices, BDX is priced at $144.43, while ZJYL trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ZJYL's P/E ratio is 16.25. In terms of profitability, BDX's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check ZJYL's competition here
BDX vs IVC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDX is priced at $144.43, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDX's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check IVC's competition here
BDX vs RVP Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, BDX is priced at $144.43, while RVP trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas RVP's P/E ratio is -3.01. In terms of profitability, BDX's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BDX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check RVP's competition here
BDX vs FEMY Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, FEMY has a market cap of 10.9M. Regarding current trading prices, BDX is priced at $144.43, while FEMY trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas FEMY's P/E ratio is -1.55. In terms of profitability, BDX's ROE is +0.05%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BDX is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check FEMY's competition here
BDX vs RGNT Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, RGNT has a market cap of 6.6M. Regarding current trading prices, BDX is priced at $144.43, while RGNT trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas RGNT's P/E ratio is -0.07. In terms of profitability, BDX's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDX is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check RGNT's competition here
BDX vs NXGL Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NXGL has a market cap of 5.3M. Regarding current trading prices, BDX is priced at $144.43, while NXGL trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NXGL's P/E ratio is -1.45. In terms of profitability, BDX's ROE is +0.05%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BDX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NXGL's competition here
BDX vs NSTG Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDX is priced at $144.43, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NSTG's competition here
BDX vs LUCY Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, LUCY has a market cap of 3.8M. Regarding current trading prices, BDX is priced at $144.43, while LUCY trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas LUCY's P/E ratio is -0.61. In terms of profitability, BDX's ROE is +0.05%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BDX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check LUCY's competition here
BDX vs POAI Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDX is priced at $144.43, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BDX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check POAI's competition here
BDX vs NXGLW Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, NXGLW has a market cap of 3.1M. Regarding current trading prices, BDX is priced at $144.43, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BDX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check NXGLW's competition here
BDX vs MHUA Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDX is priced at $144.43, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDX's ROE is +0.05%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, BDX is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check MHUA's competition here
BDX vs GMVD Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $144.43, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDX's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check GMVD's competition here
BDX vs GMVDW Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $144.43, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check GMVDW's competition here
BDX vs AVGR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDX is priced at $144.43, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDX's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check AVGR's competition here
BDX vs STSSW Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, STSSW has a market cap of 887.9K. Regarding current trading prices, BDX is priced at $144.43, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas STSSW's P/E ratio is -0.04. In terms of profitability, BDX's ROE is +0.05%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, BDX is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check STSSW's competition here
BDX vs GCTK Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, GCTK has a market cap of 380.5K. Regarding current trading prices, BDX is priced at $144.43, while GCTK trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas GCTK's P/E ratio is 0.11. In terms of profitability, BDX's ROE is +0.05%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BDX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check GCTK's competition here
BDX vs LUCYW Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDX is priced at $144.43, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BDX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check LUCYW's competition here
BDX vs WOK Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, WOK has a market cap of 587. Regarding current trading prices, BDX is priced at $144.43, while WOK trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas WOK's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to WOK's ROE of -0.07%. Regarding short-term risk, BDX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BDX.Check WOK's competition here
BDX vs IIN Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDX's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check IIN's competition here
BDX vs ATRS Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDX's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ATRS's competition here
BDX vs ARTC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ARTC's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to ARTC's ROE of N/A. Regarding short-term risk, BDX is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ARTC's competition here
BDX vs HRC Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDX's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check HRC's competition here
BDX vs APR Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas APR's P/E ratio is 22.59. In terms of profitability, BDX's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check APR's competition here
BDX vs ALOG Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas ALOG's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDX is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check ALOG's competition here
BDX vs IVTY Comparison June 2026
BDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 52.3B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDX is priced at $144.43, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 25.25, whereas IVTY's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDX is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for BDX.Check IVTY's competition here